Clinical Results

CMAB007

The ongoing phase III clinical trial of CMAB007 (NCT03468790) is a multi-center, randomized, double-blind, placebo parallel-controlled phase III study to evaluate the efficacy and safety of CMAB007 to treat asthma patients who remain inadequately controlled despite med/high dose of ICS plus LABA in China. We are currently enrolling patients for the Phase III clinical trial for CMAB007, which we expect to complete enrollment by the second quarter of 2019.

Based on our clinical results compared to published clinical results for marketed omalizumab, we believe that CMAB007 is a very promising and effective anti-IgE monoclonal antibody. The data show that CMAB007 can improve asthma patients’ conditions with lower dose inhaled corticosteroids and reduce the incidence of acute asthma attacks.

CMAB009

The pre-clinical, phase I and phase II/III clinical trials for CMAB009 have been completed. The phase III clinical trial is registered under the name of our subsidiary, Taizhou Pharmaceutical, and carried out by certain our R&D personnel, which we acquired from Biomabs in connection with the Reorganization.

Based on the clinical trial design and results, CMAB009 was clinically developed according to the new drug route, and the clinical trial results obtained were positive with statistical significance. As for the second-line treatment for KRAS wild-type and advanced colorectal cancer, the current study can show that its safety and efficacy are similar to those of marketed cetuximab drug.

CMAB008

The pre-clinical, phase I and phase II/III clinical trials for CMAB008 have been completed. The phase III clinical trial is registered under the name of our affiliate Biomabs and carried out by certain of our R&D personnel, which we acquired from Biomabs in connection with the Reorganization.

Based on the clinical trial design and results, CMAB008 is clinically developed according to the new drug route, and compared with the effectiveness and safety of the currently marketed infliximab drug. According to our clinical results compared to published results of currently marketed infliximab drug, we believe CMAB008 is safer than, and as effective as, currently marketed infliximab drug.